| Closed |
SWOG-8367 |
Combined Modality Treatment of Regional Non-Small Lung Cancer |
12/1/1983 |
10/1/1986 |
|
|
Published
|
| Closed |
SWOG-8944 |
A Study of Carboplatin (CBDCA) in Refractory Multiple Myeloma |
3/1/1990 |
6/1/1991 |
48% |
|
Published
|
| Closed |
SWOG-9436 (NABTC-9403) (NCI T94-0184) |
A Phase I/II Trial of Paclitaxel (Taxol®) Chemotherapy for Recurrent Malignant Glioma |
4/18/1995 |
2/4/1998 |
95% |
|
Published
|
| Closed |
S0533 |
Cisplatin/Etoposide/RT/Docetaxel and Three Cohorts of Bevacizumab-Advanced Stage III NSCLC |
6/15/2006 |
3/1/2010 |
16% |
|
Published
|
| Closed |
S0727 |
Pancreas Ph I/II gemcitabine, erlotinib, IMC-A12 |
3/1/2008 |
9/1/2010 |
100% |
|
Published
|
| Closed |
S0905 |
Ph I / Randomized Ph II Mesothelioma Cediranib |
3/15/2010 |
2/15/2016 |
91% |
|
Published
|
| Closed |
S0806 |
Phase I/II DLBCL Vorinostat with R-CHOP |
11/15/2010 |
10/1/2013 |
100% |
|
Published
|
| Closed |
SWOG-8825 |
Phase I Trial of Intravenous Bolus Melphalan With GM-CSF |
12/15/1988 |
12/1/1990 |
87% |
|
Published
|
| Closed |
SWOG-8903 |
Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma |
11/15/1989 |
11/1/1993 |
93% |
|
Published
|
| Closed |
SWOG-8902 |
Phase I Trial of Doxorubicin plus Carboplatin with GM-CSF in Patients with Advanced, Previously Treated Cancer |
4/15/1990 |
5/1/1992 |
70% |
|
Published
|
| Closed |
SWOG-8833 |
Phase ll Investigation of Chlorambucil and Fludarabine Monophosphate in Relapsed or Refractory Chronic Lymphocytic Leukemia |
5/15/1989 |
4/15/1991 |
88% |
|
Published
|
| Closed |
SWOG-8746 |
Phase I Trial of Dose Intensive Chemotherapy Combined with Granulocyte-Macrophage Colony Stimulating Factor in Advanced Breast Cancer |
9/1/1988 |
9/1/1992 |
67% |
|
Published
|
| Closed |
SWOG-8940 |
A Phase I Study of the Combination of Recombinant Human Interleukin 1-Beta, Etoposide, and Carboplatin in Patients with Metastatic Cancer |
3/1/1990 |
11/1/1992 |
100% |
|
Published
|
| Closed |
S9617 |
A Phase I Study of PSC833 As Chemotherapy – Resistance Modifier in Patients Over Age 55 With Previously Untreated Myeloid Leukemia (AML). |
11/1/1996 |
9/1/1998 |
100% |
|
Published
|
| Closed |
SWOG-8922 |
Phase I Trial of Doxorubicin, DTIC and Ifosfamide with Recombinant Granulocyte-Macrophage Colony Stimulating Factor in Advanced Soft Tissue Sarcomas |
9/15/1990 |
9/15/1992 |
28% |
|
Published
|
| Closed |
SWOG-8801 |
A Study of the Sequential Combination of Recombinant Interferon Gamma (rIFN-y) and Recombinant Interleukin-2 (rIL-2) in Patients with Disseminated Malignant Disease |
10/1/1988 |
1/1/1990 |
100% |
|
Published
|
| Closed |
SWOG-9026 |
A Phase I, Open Label, Multicenter Study of the Safety, Tolerability and Biological Effects of SDZ ILE 964 (Recombinant Human Interleukin-3), Administered to Patients with Metastatic Cancer Prior to… |
7/15/1991 |
9/29/1992 |
100% |
|
Published
|
| Closed |
S0004 |
Tirapazamine/Cis/Etopo/RT in Limited SCLC |
10/15/2000 |
4/1/2002 |
60% |
|
Published
|
| Closed |
S0355 |
Phase I Pharmacokinetic Study |
11/1/2003 |
8/15/2006 |
100% |
|
Published
|
| Closed |
S0429 |
Docetaxel and Cetuximab Chemoradiation in Stage III NSCLC |
4/1/2006 |
8/15/2009 |
40% |
|
Published
|
